Read · November 9, 2026

The FDA orders a new warning on all GLP-1 drugs, including Ozempic and Wegovy, for a rare eye condition that can cause vision loss

• From the LeftCBS News: CBS quotes a co-author of the 2024 study and both drugmakers; the FDA puts the rate near 6 in 100,000.

  CBS quotes a co-author of the 2024 study and both drugmakers; the FDA puts the rate near 6 in 100,000.

  Grade: A (97/100). Lehrer score 97/100 (starts at 85; +4 named, on-record sources (2+): Dr. Joseph Rizzo, Novo Nordisk and Eli Lilly quoted by name; +4 other side quoted or given its response: Novo Nordisk "continues to believe the data do not establish a cause-and-effect relationship"; +2 key numbers sourced: "roughly 6 of every 100,000 patients who took a GLP-1 for at least one year," the FDA said; +2 context: background or what came before: NAION "affects somewhere between 2 to 10 of every 100,000 adults over age 50, according to the American Academy of Ophthalmology"). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → A.

• CenterCNBC: CNBC gives the FDA's trial count, 6.4 vs 3.8 cases per 100,000 patient-years, and Citi's view on demand.

  CNBC gives the FDA's trial count, 6.4 vs 3.8 cases per 100,000 patient-years, and Citi's view on demand.

  Grade: A (97/100). Lehrer score 97/100 (starts at 85; +4 named, on-record sources (2+): Novo Nordisk and Citi analysts quoted by name; +4 other side quoted or given its response: Novo Nordisk says the data "do not establish a cause-and-effect relationship"; +2 key numbers sourced: "An analysis of 126 trials involving more than 134,000 patients found 6.4 cases of NAION per 100,000 patient-years"; +2 context: background or what came before: the drugs already carry a boxed warning over "a potential risk of thyroid tumors"). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → A.

• From the RightNew York Post: The Post leads with blindness and a 2024 study, and leaves out the drugmakers' response.

  The Post leads with blindness and a 2024 study, and leaves out the drugmakers' response.

  Grade: C (72/100). Lehrer score 72/100 (starts at 85; +3 primary document linked or cited (filing, ruling, data release, statement): the FDA's Nov. 9 drug safety communication quoted: "Consider discontinuing the GLP-1 RA in patients who develop NAION"; +2 context: background or what came before: "The warning follows a 2024 study"; −6 leaves out a fact or voice the other two pieces report / one side only (rule 5/13): leaves out the drugmakers' response, which CBS News and CNBC both report (Novo Nordisk: the data "do not establish a cause-and-effect relationship"); −6 leaves out a fact or voice the other two pieces report / one side only (rule 5/13): leaves out how rare the cases were in the FDA's trial review (about 6 in 100,000), which CBS News and CNBC both report; −3 talks down to the audience: bait headline or tease the piece doesn't deliver (rule 6): headline "incurable blindness condition" for what the FDA calls a "potential increased risk of rare NAION events"; −3 entertainment framing in news: hype, stings, celebrity angle over substance (rule 16): opens with a pun: "You're going to want to keep an eye on this."). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → C.

See it on the Read page · All stories from November 10, 2026 · How we grade · Previous story · Next story